Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 19/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 17/20 | 0.42 |
| ▸ | CCND1 | P24385 | 16/20 | 0.42 |
| ▸ | CDK6 | Q00534 | 14/20 | 0.42 |
| ▸ | CDK4 | P11802 | 5/20 | 0.42 |
| ▸ | CDK1 | P06493 | 3/20 | 0.42 |
| ▸ | CCND3 | P30281 | 3/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.42 |
| ▸ | CDK9 | P50750 | 2/20 | 0.42 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.42 |
| ▸ | RB1 | P06400 | 1/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27033325 | 1.00 | GPR119 (0.43) | GPR119CDK2CCNE1CCND1CDK6 | |
| SCHEMBL27033317 | 0.95 | CDK2 (0.42) | GPR119CDK2CCNE1CCND1CDK6 | |
| SCHEMBL30726192 | 0.95 | CDK2 (0.42) | GPR119CDK2CCNE1CCND1CDK6 | |
| SCHEMBL27064223 | 0.90 | GPR119 (0.49) | GPR119CDK2CCNE1CCND1CDK6 | |
| SCHEMBL27033388 | 0.86 | CCNE1 (0.48) | CDK2CCNE1CCND1CDK6CDK4 | |
| SCHEMBL30726229 | 0.86 | CCNE1 (0.48) | CDK2CCNE1CCND1CDK6CDK4 | |
| SCHEMBL30726234 | 0.83 | CDK2 (0.48) | CDK2CCNE1CCND1CDK6CDK4 | |
| SCHEMBL27033306 | 0.83 | CDK2 (0.48) | CDK2CCNE1CCND1CDK6CDK4 | |
| SCHEMBL31538948 | 0.82 | CDK2 (0.45) | CDK2CCNE1CCND1CDK6CDK4 | |
| SCHEMBL27033514 | 0.82 | CDK2 (0.45) | CDK2CCNE1CCND1CDK6CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4558493-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE | Iambic Therapeutics, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| CN-119894880-A | Quinazoline compounds and methods of use | 依安彼克医疗有限公司 | 2025-04-25 | — | — | CN | disclosed |
| WO-2024020380-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |